Sumitomo Dainippon Pharma Annual Report 2017
90/102

Millions of yenThousands ofU.S. dollars201620172017Millions of yenThousands ofU.S. dollars201620172017Millions of yenThousands ofU.S. dollars201620172017Millions of yenThousands ofU.S. dollars201620172017$ 2,30465,634¥ 2687,633¥ 2587,351SalesPurchases $ 33,2957,607(266,563)2,134¥ 3,6731,138 2,089 292¥ 3,729852(29,855)239Purchases of products Payment of other expenses Loans (Collection) Interest income $ 8,482 52,420 $ 60,902 ¥ 1,0106,656 ¥ 7,666 ¥ 9505,871 ¥ 6,821Due within one yearDue after one yearTotal$ 150,0549,063¥ 48,553666¥ 16,8061,015ReceivablesPayablesThe balances due to or from the parent company, Sumitomo Chemical Co., Ltd., as at March 31, 2017 and 2016 were as follows:Transactions of the Group with the parent company, Sumitomo Chemical Co., Ltd., unconsolidated subsidiaries and afliates for the years ended March 31, 2017 and 2016 were as follows:12. TRANSACTIONS WITH PARENT COMPANY, UNCONSOLIDATED SUBSIDIARIES AND AFFILIATESBusiness combination through acquisitionCynapsus Therapeutics Inc.a. Summary of the business combination1. Name of the acquired company and the contents of its business operationsName of the acquired company: Cynapsus Therapeutics Inc. (“Cynapsas”)Contents of the business operations: Developing pharmaceuticals for Parkinson’s disease2. Main reason for the business combinationSunovion Pharmaceuticals Inc.(“Sunovion”) focuses on the Psychiatry & Neurology area and promotes the atypical antipsychotic agent Latuda® and antiepileptic drug Aptiom®. Sunovion concluded that this acquisition contribute to expand Psychiatry & Neurology portfolio, one of its key therapeutic areas, through the acquisition of Cynapsus and their product for Parkinson’s disease.15. BUSINESS COMBINATIONSMajor transactions of the Group with the parent company, Sumitomo Chemical Co., Ltd., for the years ended March 31, 2017 and 2016 were as follows:13. RELATED PARTY TRANSACTIONSThe minimum lease payments under non-cancelable operating leases as of March 31, 2017 and 2016 were as follows:14. LEASESNotes to Consolidated Financial StatementsSumitomo Dainippon Pharma Co., Ltd. and Consolidated SubsidiariesYears Ended March 31, 2017 and 2016Financial SectionSumitomo Dainippon Pharma Co., Ltd. Annual Report 201789

元のページ  ../index.html#90

このブックを見る